Serial magnetic resonance imaging detects a rapid reduction in plaque lipid content under PCSK9 inhibition with alirocumab.
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
/ adverse effects
Anticholesteremic Agents
/ adverse effects
Biomarkers
/ blood
Carotid Artery Diseases
/ blood
Cholesterol, HDL
/ blood
Cholesterol, LDL
/ blood
Female
Humans
Magnetic Resonance Imaging
Male
Middle Aged
PCSK9 Inhibitors
Plaque, Atherosclerotic
Predictive Value of Tests
Proof of Concept Study
Serine Proteinase Inhibitors
/ pharmacology
Time Factors
Treatment Outcome
Alirocumab
Carotid plaque
LDL
Magnetic resonance imaging
PCSK9
Journal
The international journal of cardiovascular imaging
ISSN: 1875-8312
Titre abrégé: Int J Cardiovasc Imaging
Pays: United States
ID NLM: 100969716
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
16
07
2020
accepted:
21
11
2020
pubmed:
5
1
2021
medline:
6
7
2021
entrez:
4
1
2021
Statut:
ppublish
Résumé
PCSK9 inhibitors lower low-density lipoprotein cholesterol (LDL-C) and reduce cardiovascular events. The clinical benefits presumably result from favorable effects on atherosclerotic plaques. Lipid-core and plaque inflammation have been recognized as main determinants of risk for plaque rupture and cardiovascular events. Both can be noninvasively assessed with carotid MRI. We studied if PCSK9 inhibition with alirocumab induces regression in lipid-core or plaque inflammation within 6 months as measured by MRI. Patients with non-calcified carotid plaque(s) and baseline LDL-C ≥ 70 mg/dl, who were statin-intolerant or taking a low-dose statin (≤ 10 mg per day of atorvastatin or an equivalent), received subcutaneous alirocumab 150 mg every 2 weeks. Carotid MRI was performed at baseline and 6 months after treatment, including pre- and post-contrast images for measuring percent lipid-core volume (%LC) and dynamic contrast-enhanced images for measuring microvessel leakiness (K
Identifiants
pubmed: 33392875
doi: 10.1007/s10554-020-02115-w
pii: 10.1007/s10554-020-02115-w
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Anticholesteremic Agents
0
Biomarkers
0
Cholesterol, HDL
0
Cholesterol, LDL
0
PCSK9 Inhibitors
0
Serine Proteinase Inhibitors
0
PCSK9 protein, human
EC 3.4.21.-
alirocumab
PP0SHH6V16
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1415-1422Références
Grundy SM, Stone NJ, Bailey AL et al (2019) 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation 139:e1082–e1143
Sabatine MS, Giugliano RP, Keech AC et al (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376:1713–1722
doi: 10.1056/NEJMoa1615664
Schwartz GG, Steg PG, Szarek M et al (2018) Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 379:2097–2107
doi: 10.1056/NEJMoa1801174
Arbab-Zadeh A, Nakano M, Virmani R, Fuster V (2012) Acute coronary events. Circulation 125:1147–1156
doi: 10.1161/CIRCULATIONAHA.111.047431
Narula J, Nakano M, Virmani R et al (2013) Histopathologic characteristics of atherosclerotic coronary disease and implications of the findings for the invasive and noninvasive detection of vulnerable plaques. J Am Coll Cardiol 61:1041–1051
doi: 10.1016/j.jacc.2012.10.054
Cai JM, Hatsukami TS, Ferguson MS et al (2005) In vivo quantitative measurement of intact fibrous cap and lipid-rich necrotic core size in atherosclerotic carotid plaque: comparison of high-resolution, contrast-enhanced magnetic resonance imaging and histology. Circulation 112:3437–3444
doi: 10.1161/CIRCULATIONAHA.104.528174
Wasserman BA, Smith WI, Trout HH, Cannon RO, Balaban RS, Arai AE (2002) Carotid artery atherosclerosis: in vivo morphologic characterization with gadolinium-enhanced double-oblique MR imaging–initial results. Radiology 223:566–573
doi: 10.1148/radiol.2232010659
Trivedi RA, U-King-Im J, Graves MJ et al (2004) Multi-sequence in vivo MRI can quantify fibrous cap and lipid core components in human carotid atherosclerotic plaques. Eur J Vasc Endovasc Surg 28:207–213
doi: 10.1016/j.ejvs.2004.05.001
Kerwin WS, O’Brien KD, Ferguson MS, Polissar N, Hatsukami TS, Yuan C (2006) Inflammation in carotid atherosclerotic plaque: a dynamic contrast-enhanced MR imaging study. Radiology 241:459–468
doi: 10.1148/radiol.2412051336
Gaens ME, Backes WH, Rozel S et al (2013) Dynamic contrast-enhanced MR imaging of carotid atherosclerotic plaque: model selection, reproducibility, and validation. Radiology 266:271–279
doi: 10.1148/radiol.12120499
Taqueti VR, Di Carli MF, Jerosch-Herold M et al (2014) Increased microvascularization and vessel permeability associate with active inflammation in human atheromata. Circ Cardiovasc Imaging 7:920–929
doi: 10.1161/CIRCIMAGING.114.002113
Zavodni AE, Wasserman BA, McClelland RL et al (2014) Carotid artery plaque morphology and composition in relation to incident cardiovascular events: the Multi-Ethnic Study of Atherosclerosis (MESA). Radiology 271:381–389
doi: 10.1148/radiol.14131020
Sun J, Zhao XQ, Balu N et al (2017) Carotid plaque lipid content and fibrous cap status predict systemic CV outcomes: the MRI substudy in AIM-HIGH. JACC Cardiovasc Imaging 10:241–249
doi: 10.1016/j.jcmg.2016.06.017
Honda O, Sugiyama S, Kugiyama K et al (2004) Echolucent carotid plaques predict future coronary events in patients with coronary artery disease. J Am Coll Cardiol 43:1177–1184
doi: 10.1016/j.jacc.2003.09.063
Ogata A, Oho K, Matsumoto N et al (2019) Stabilization of vulnerable carotid plaques with proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab. Acta Neurochir (Wien) 161:597–600
doi: 10.1007/s00701-019-03825-4
Sun J, Balu N, Hippe DS et al (2013) Subclinical carotid atherosclerosis: short-term natural history of lipid-rich necrotic core—a multicenter study with MR imaging. Radiology 268:61–68
doi: 10.1148/radiol.13121702
Underhill HR, Yuan C, Zhao XQ et al (2008) Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J 155:581–584
doi: 10.1016/j.ahj.2007.11.018
Sun J, Zhao XQ, Balu N et al (2015) Carotid magnetic resonance imaging for monitoring atherosclerotic plaque progression: a multicenter reproducibility study. Int J Cardiovasc Imaging 31:95–103
doi: 10.1007/s10554-014-0532-7
Kerwin WS, Xu D, Liu F et al (2007) Magnetic resonance imaging of carotid atherosclerosis: plaque analysis. Top Magn Reson Imaging 18:371–378
doi: 10.1097/rmr.0b013e3181598d9d
Takaya N, Cai JM, Ferguson MS et al (2006) Intra- and interreader reproducibility of magnetic resonance imaging for quantifying the lipid-rich necrotic core is improved with gadolinium contrast enhancement. J Magn Reson Imaging 24:203–210
doi: 10.1002/jmri.20599
Dong L, Kerwin WS, Chen H et al (2011) Carotid artery atherosclerosis: effect of intensive lipid therapy on the vasa vasorum-evaluation by using dynamic contrast-enhanced MR imaging. Radiology 260:224–231
doi: 10.1148/radiol.11101264
Kerwin WS, Oikawa M, Yuan C, Jarvik GP, Hatsukami TS (2008) MR imaging of adventitial vasa vasorum in carotid atherosclerosis. Magn Reson Med 59:507–514
doi: 10.1002/mrm.21532
Gupta A, Baradaran H, Schweitzer AD et al (2013) Carotid plaque MRI and stroke risk: a systematic review and meta-analysis. Stroke 44:3071–3077
doi: 10.1161/STROKEAHA.113.002551
Zhao XQ, Dong L, Hatsukami T et al (2011) MR imaging of carotid plaque composition during lipid-lowering therapy: a prospective assessment of effect and time course. J Am Coll Cardiol Img 4:977–986
doi: 10.1016/j.jcmg.2011.06.013
Brinjikji W, Lehman VT, Kallmes DF et al (2017) The effects of statin therapy on carotid plaque composition and volume: a systematic review and meta-analysis. J Neuroradiol 44:234–240
doi: 10.1016/j.neurad.2016.12.004
Hoogeveen RM, Opstal TSJ, Kaiser Y et al (2019) PCSK9 Antibody alirocumab attenuates arterial wall inflammation without changes in circulating inflammatory markers. JACC Cardiovasc Imaging 12:2571–2573
Vlachopoulos C, Koutagiar I, Skoumas I et al (2019) Long-term administration of proprotein convertase subtilisin/kexin type 9 inhibitors reduces arterial FDG uptake. JACC Cardiovasc Imaging 12:2573–2574
doi: 10.1016/j.jcmg.2019.09.024
Banach M, Serban C, Sahebkar A et al (2015) Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. BMC Med 13:229
doi: 10.1186/s12916-015-0459-4
Andelius L, Mortensen MB, Norgaard BL, Abdulla J (2018) Impact of statin therapy on coronary plaque burden and composition assessed by coronary computed tomographic angiography: a systematic review and meta-analysis. Eur Heart J Cardiovasc Imaging 19:850–858
doi: 10.1093/ehjci/jey012
Kini AS, Baber U, Kovacic JC et al (2013) Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy). J Am Coll Cardiol 62:21–29
doi: 10.1016/j.jacc.2013.03.058
Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J (2001) Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques—implications for plaque stabilization. Circulation 103:926–933
doi: 10.1161/01.CIR.103.7.926
Tsujita K, Sugiyama S, Sumida H et al (2015) Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial. J Am Coll Cardiol 66:495–507
doi: 10.1016/j.jacc.2015.05.065
Nicholls SJ, Puri R, Anderson T et al (2016) Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA 316:2373–2384
doi: 10.1001/jama.2016.16951
Nicholls SJ, Puri R, Anderson T et al (2018) Effect of evolocumab on coronary plaque composition. J Am Coll Cardiol 72:2012–2021
doi: 10.1016/j.jacc.2018.06.078
Stiekema LCA, Stroes ESG, Verweij SL et al (2019) Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment. Eur Heart J 40:2775–2781
doi: 10.1093/eurheartj/ehy862
Calcagno C, Ramachandran S, Izquierdo-Garcia D et al (2013) The complementary roles of dynamic contrast-enhanced MRI and F-fluorodeoxyglucose PET/CT for imaging of carotid atherosclerosis. Eur J Nucl Med Mol Imaging 40:1884–1893
doi: 10.1007/s00259-013-2518-4
Truijman MTB, Kwee RM, van Hoof RHM et al (2013) Combined 18F-FDG PET-CT and DCE-MRI to assess inflammation and microvascularization in atherosclerotic plaques. Stroke 44:3568–3570
doi: 10.1161/STROKEAHA.113.003140
Wang J, Liu H, Sun J et al (2014) Varying correlation between 18F-fluorodeoxyglucose positron emission tomography and dynamic contrast-enhanced MRI in carotid atherosclerosis: implications for plaque inflammation. Stroke 45:1842–1845
doi: 10.1161/STROKEAHA.114.005147
Chai JT, Biasiolli L, Li L et al (2017) Quantification of lipid-rich core in carotid atherosclerosis using MRI T2 mapping—relation to clinical presentation. J Am Coll Cardiol Img 10:747–756
doi: 10.1016/j.jcmg.2016.06.013
Qi H, Sun J, Qiao H et al (2018) Simultaneous T1 and T2 mapping of the carotid plaque (SIMPLE) with T2 and inversion recovery prepared 3D radial imaging. Magn Reson Med 80:2598–2608
doi: 10.1002/mrm.27361